Debra Barker, MD

Senior Independent Director, Switzerland

Dr. Debra Barker is a seasoned International Life Sciences executive with more than 25 years’ senior experience in major pharmaceutical companies- Roche, SmithKline Beecham and most extensively Novartis where she held several senior scientific, operational and commercial roles over 17 years, including Development Head for Infectious Diseases, Immunology and Transplantation, Global Programme Head in Oncology and Head of Clinical and Medical Services. Biotech experience was gained in Chief Medical Officer & Head of Development roles and Debra was also the medical lead for the Swiss based Biotech Polyphor’s highly successful IPO on the SIX Swiss Exchange.

Debra is currently serving as a Non-Executive Director for three public Biotechnology companies listed in UK, EU & USA namely Destiny Pharma PLC, BergenBio ASA and CureVac NV.

Debra is Chair of the Remuneration Committee at Destiny Pharma PLC and a member of the Remuneration Committee at BergenBio ASA.

As of May 2023, Debra was appointed as Interim Chief Executive Officer of Destiny Pharma.

She has a Diploma in Pharmaceutical Medicine and received a MSc in Immunology from the King's College in London and a Medical Degree from the Queens’ College, Cambridge, UK.

Debra joined the Arix Board in August 2022 and is Chair of the Remuneration Committee and a member of the Audit Committee, Nomination Committee and Strategy & Investment Committee.